Current Hematologic Malignancy Reports

, Volume 8, Issue 1, pp 43–51

Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia

Chronic Leukemias (J Goldman, Section Editor)

Abstract

In recent years new, more potent tyrosine-kinase inhibitors have been introduced to accompany imatinib for the treatment of chronic myeloid leukemia. Most patients in chronic phase obtain an optimal response to these oral agents with minimal toxicity. Allogeneic stem cell transplantation is therefore indicated only in a minority of patients who do not achieve an adequate response to first, second or third generation agents. Patients in accelerated phase have a lower chance of achieving an optimal response on these drugs. For patients in blast phase, transplantation remains the only therapy with curative potential, although now it is increasingly used in combination with tyrosine-kinase inhibitors. In this review we address the role of allogeneic stem cell transplantation in the treatment of this disease and how patients should be transplanted.

Keywords

Chronic myeloid leukemia CML Allogeneic stem cell transplantation BMT Tyrosine-kinase inhibitor TKI Graft-versus-leukemia effect 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Geary CG. The story of chronic myeloid leukaemia. Br J Haematol. 2000;110:2–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Fefer A, Cheever MA, Thomas ED, et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med. 1979;300:333–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011;117:755–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Barnes DW, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J. 1956;2:626–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Graw Jr RG, Buckner CD, Whang-Peng J, et al. Complication of bone marrow transplantation. Graft-versus-host disease resulting from chronic myelogenous leukaemia leucocyte transfusions. Lancet. 1970;2:338–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Odom LF, August CS, Githens JH, et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A “graft-versus-leukaemia reaction” in man? Lancet. 1978;2:537–40.PubMedCrossRefGoogle Scholar
  7. 7.
    Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–73.PubMedCrossRefGoogle Scholar
  8. 8.
    Apperley JF, Jones L, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1986;1:53–66.PubMedGoogle Scholar
  9. 9.
    Horowitz MM, Gale RP, Sondel PM, et al. Graft- versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62.PubMedGoogle Scholar
  10. 10.
    Ringden O, Zwaan F, Hermans J, Gratwohl A. European experience of bone marrow transplantation for leukemia. Transplant Proc. 1987;19:2600–4.PubMedGoogle Scholar
  11. 11.
    Fefer A, Sullivan KM, Weiden PL, et al. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than syngeneic marrow transplantation. In: Truitt RL, Gale RP, Bortin MM, editors. Cellular immunotherapy of cancer. New York: A.R. Liss; 1987. p. 401–8.Google Scholar
  12. 12.
    Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 1999;94:1201–8.PubMedGoogle Scholar
  13. 13.
    Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88:3223–9.PubMedGoogle Scholar
  14. 14.
    Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Rezvani K, Yong AS, Savani BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood. 2007;110:1924–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102:2892–900.PubMedCrossRefGoogle Scholar
  17. 17.
    Butt NM, Rojas JM, Wang L, et al. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica. 2005;90:1315–23.PubMedGoogle Scholar
  18. 18.
    Yong AS, Stephens N, Weber G, et al. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia. 2011;25:629–37.PubMedCrossRefGoogle Scholar
  19. 19.
    • Bornhäuser M, Thiede C, Platzbecker U, et al. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood. 2011;117:7174–84. Donor-derived dendritic cells generated in vitro were loaded with human leukocyte antigen-restricted peptides derived from PR1, WT1, and/or BCR-ABL and used to stimulate donor CD8+ T cells. The stimulated T cells were infused to patients after T-cell depleted transplantation, with promising results and no GvHD.PubMedCrossRefGoogle Scholar
  20. 20.
    Yong AS, Keyvanfar K, Eniafe R, et al. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia. 2008;22:1721–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV. The polycomb group BMI-1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood. 2007;110:380–3.PubMedCrossRefGoogle Scholar
  22. 22.
    Kaeda J, O’Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood. 2006;107:4171–6.PubMedCrossRefGoogle Scholar
  23. 23.
    de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358–63.PubMedCrossRefGoogle Scholar
  24. 24.
    Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319–25.PubMedCrossRefGoogle Scholar
  25. 25.
    Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532–9.PubMedCrossRefGoogle Scholar
  26. 26.
    • Warlick E, Ahn KW, Pedersen TL, et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood. 2012;119:4083–90. CIBMTR data analysis of 306 CML patients >39 years old transplanted between 2001 and 2007. Their survival was similar across the ages, but the relapse incidence was higher in patients >69 years old with no significant difference apparent in those transplanted in the first chronic phase. Nonmyeloablative conditioning/reduced intensity conditioning was inferior to more intensive conditioning.PubMedCrossRefGoogle Scholar
  27. 27.
    Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 2003;101:441–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106:2969–76.PubMedCrossRefGoogle Scholar
  29. 29.
    Martin PJ, Hansen JA, Buckner CD, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 1985;66:664–72.PubMedGoogle Scholar
  30. 30.
    Soiffer RJ, Martin P. T-cell depletion of allogenetic hematopoietic stem cell grafts. In: Atkinson K, Champlin RE, Ritz J, Fibbe WE, Ljungman P, Brenner MK, editors. Clinical bone marrow and blood stem cell transplantation. Cambridge, UK: Cambridge University Press; 2004. p. 416–25.Google Scholar
  31. 31.
    Lee SJ, Zahrieh D, Alyea EP, et al. Comparison of T-cell depleted and non-T-cell depleted unrelated donor transplantations for hematologic diseases: clinical outcomes, quality of life, and costs. Blood. 2002;100:2697–702.PubMedCrossRefGoogle Scholar
  32. 32.
    Sehn LH, Alyea EP, Weller E, et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999;17:561–8.PubMedGoogle Scholar
  33. 33.
    Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR/ABL transcripts by quantitative RT-PCR predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2001;97:1560–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Oehler VG, Radich JP, Storer B, et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant. 2005;11:85–92.PubMedCrossRefGoogle Scholar
  35. 35.
    Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91:513–21.PubMedGoogle Scholar
  36. 36.
    Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008;112:3500–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Weisdorf DJ, Nelson G, Lee SJ, et al. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for CML: refined HLA-matching shows more GVHD but not less relapse. Biol Blood Marrow Transplant. 2009;15:1475–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Laporte JP, Gorin NC, Rubinstein P, et al. Cord blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. N Engl J Med. 1996;335:167–70.PubMedCrossRefGoogle Scholar
  39. 39.
    • Sanz J, Montesinos P, Saavedra S, et al. Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myeloid leukemia. Biol Blood Marrow Transplant. 2010;16:1589–95. A retrospective single-center study of 26 adults with CML receiving unrelated cord blood SCT.PubMedCrossRefGoogle Scholar
  40. 40.
    Nagamura-Inoue T, Kai S, Azuma H, et al. Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. Bone Marrow Transplant. 2008;42:241–51.PubMedCrossRefGoogle Scholar
  41. 41.
    Huang XJ, Xu LP, Liu KY, et al. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med. 2008;40:444–55.CrossRefGoogle Scholar
  42. 42.
    Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009;22:355–65.PubMedCrossRefGoogle Scholar
  43. 43.
    • Goldman JM, Majhail NS, Klein JP, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28:1888–95. This CIBMTR study of 2,444 patients who had survived in continuous complete remission for at least 5 years after SCT for CML in the first chronic phase showed a survival rate of 88 % at 15 years for sibling transplant recipients and 87 % for unrelated recipients. The corresponding incidences of relapse were only 8 % and 2 %, respectively, with the last relapse 18 years after SCT.PubMedCrossRefGoogle Scholar
  44. 44.
    Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2000;96:2712–6.PubMedGoogle Scholar
  45. 45.
    Chalandon Y, Passweg JR, Schmid C, et al. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2010;45:558–64.PubMedCrossRefGoogle Scholar
  46. 46.
    Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2003;17:1707–12.PubMedCrossRefGoogle Scholar
  47. 47.
    Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol. 2005;23:7583–93.PubMedCrossRefGoogle Scholar
  48. 48.
    Atallah E, Kantarjian H, De Lima M, et al. The role of dasatinib in patients with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT) (American Society of Hematology Annual Meeting Abstracts). Blood. 2006;108:abstract 4520.Google Scholar
  49. 49.
    Klyuchnikov E, Schafhausen P, Kroger N, et al. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol. 2009;122:6–10.PubMedCrossRefGoogle Scholar
  50. 50.
    Kantarjian HM, O’Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002;100:1590–5.PubMedGoogle Scholar
  51. 51.
    Weisser M, Tischer J, Schnittger S, et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica. 2006;91:663–6.PubMedGoogle Scholar
  52. 52.
    Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36:1009–15.PubMedCrossRefGoogle Scholar
  53. 53.
    Garland P, Dazzi F, Marin D. Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML. Bone Marrow Transplant. 2010;45:395–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Olavarria E, Siddique S, Griffiths MJ, et al. Post-transplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood. 2007;110:4614–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007;109:2791–3.PubMedGoogle Scholar
  56. 56.
    • Sauselle S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in the imatinib era; evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010;115:1880–5. A multicenter study of 84 patients who underwent SCT after pretreatment with imatinib. Patients with EBMT score 0 or 1 had SCT early (n = 19), 37 patients after imatinib failure, and 28 patients for advanced phase disease. With a median follow up of 24 months the estimated 3-year survival of patients in chronic and advanced phase was 91 % and 59 %, respectively.CrossRefGoogle Scholar
  57. 57.
    Jabbour E, Cortes J, Santos FP, et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011;117:3641–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011;118:5697–700.PubMedCrossRefGoogle Scholar
  59. 59.
    Marin D. Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. American Society of Hematology Education Program. 2012. In press.Google Scholar
  60. 60.
    Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841–51.PubMedCrossRefGoogle Scholar
  62. 62.
    Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Milojkovic D, Apperley JF, Gerrard G, et al. Responses to second line tyrosine kinase inhibitors are durable: an intention to treat analysis in chronic myeloid leukemia patients. Blood. 2012;119:1838–43.PubMedCrossRefGoogle Scholar
  64. 64.
    Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567–76.PubMedCrossRefGoogle Scholar
  65. 65.
    Garg RJ, Kantarjian H, O’Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009;114:4361–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Ibrahim AR, Paliompeis C, Bua M, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010;116:5497–500.PubMedCrossRefGoogle Scholar
  67. 67.
    Cortes JE, Feldman EJ, Yee K, et al. Subset analysis of response to treatment of chronic phase CML in a phase 1 study of ponatinib in refractory hematologic malignancies (American Society of Hematology Annual Meeting Abstracts). Blood 2011;118:abstract 601.Google Scholar
  68. 68.
    Cortes JE, Talpaz M, Kantarjian HM, et al. A phase 1 study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph+) leukemias including patients with T315I mutation (American Society of Hematology Annual Meeting Abstracts). Blood. 2011;118:abstract 601.Google Scholar
  69. 69.
    Carella AM, Goldman JM, Martinelli G, et al. Chronic myeloid leukemia: the basis of treatment for tomorrow. Haematologica. 2011;96:1737–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087–92.PubMedCrossRefGoogle Scholar
  71. 71.
    Passweg JR, Walker I, Sobocinski KA, et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol. 2004;125:613–20.PubMedCrossRefGoogle Scholar
  72. 72.
    Pavlu J, Kew A, Taylor-Roberts B, et al. Optimizing patient selection for allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood. 2010;115:4018–20.PubMedCrossRefGoogle Scholar
  73. 73.
    Ibrahim AR, Clark RE, Holyoake TL, et al. Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica. 2011;96:1779–82.PubMedCrossRefGoogle Scholar
  74. 74.
    Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–51.PubMedCrossRefGoogle Scholar
  75. 75.
    Jabbour E, Kantarjian HM, O’Brien S, et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol. 2011;29:4260–5.PubMedCrossRefGoogle Scholar
  76. 76.
    Wang L, Pearson K, Ferguson JE, et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003:990–999.Google Scholar
  77. 77.
    Hanfstein B, Müller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26:2096–102.PubMedCrossRefGoogle Scholar
  78. 78.
    Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758–65.PubMedCrossRefGoogle Scholar
  79. 79.
    Marin D, Hedgley C, Clark RE, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first line dasatinib. Blood. 2012;120:291–4.PubMedCrossRefGoogle Scholar
  80. 80.
    Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928–37.PubMedCrossRefGoogle Scholar
  81. 81.
    Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica. 2009;94:205–12.PubMedCrossRefGoogle Scholar
  82. 82.
    Rea D, Etienne G, Nicolini F, et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia. 2012;26:2254–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113:6322–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Le Coutre PD, Giles FJ, Hochhaus A, et al. Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012;26:1189–94.PubMedCrossRefGoogle Scholar
  85. 85.
    • Khoury HJ, Kukreja M, Goldman JM, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2012;47:810–6. A CIBMTR study of 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML. Estimated 3-year survival was 35–50 % for second chronic phase, 29–43 % for accelerated phase and 8–23 % for blast phase.PubMedCrossRefGoogle Scholar
  86. 86.
    Jiang Q, Xu LP, Liu DH, et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood. 2011;117:3032–40.PubMedCrossRefGoogle Scholar
  87. 87.
    Visani G, Rosti G, Bandini G, et al. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol. 2000;109:722–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Fruehauf S, Topaly J, Buss EC, et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 2007;109:1543–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Milojkovic D, Ibrahim A, Reid A, et al. Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematologica. 2012;97:473–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Imperial College London at Hammersmith HospitalLondonUK
  2. 2.Department of Haematology, Imperial College Healthcare NHS TrustHammersmith HospitalLondonUK
  3. 3.Centre for HaematologyFaculty of MedicineLondonUK

Personalised recommendations